Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Polycystic ovary syndrome (PCOS) affects an estimated 8–13% of women of reproductive age and is the most common cause of anovulatory infertility. Its central mechanism — insulin resistance driving hyperandrogenism — means semaglutide is increasingly recognised as a highly relevant treatment option.
Why GLP-1 Is Mechanistically Relevant to PCOS
Insulin resistance causes the ovarian theca cells to overproduce androgens (testosterone, androstenedione) in response to elevated insulin. These excess androgens disrupt follicular development, causing the characteristic polycystic ovarian morphology, anovulation, irregular periods, acne, and hirsutism of PCOS. Semaglutide improving insulin sensitivity directly reduces this androgenic drive — not just as a downstream effect of weight loss, but through direct metabolic improvement in insulin signalling.
Clinical Evidence
A 2022 randomised controlled trial published in Diabetes Care showed that semaglutide (versus placebo) in women with PCOS and overweight significantly reduced free testosterone, improved menstrual frequency, reduced hirsutism scores, and improved metabolic markers. Multiple cohort studies and case series report similar findings. The effect appears to be additive to metformin — the current first-line treatment for PCOS with insulin resistance — with better tolerability than metformin at high doses.
Menstrual Regularity and Fertility
One of the most reported benefits of semaglutide in women with PCOS is the return of regular menstrual cycles. Women who have been anovulatory for years frequently report their cycle resuming within 2–4 months of starting treatment. For women pursuing fertility, this restoration of ovulation is significant — though it also means unintended pregnancy risk increases and contraception planning is needed.
Important Pregnancy Warning
Semaglutide must be stopped at least 2 months before attempting conception and must not be used during pregnancy. Animal studies show fetal harm at high doses. If you are planning pregnancy while managing PCOS with semaglutide, create a clear transition plan with your prescriber well in advance of trying to conceive.
PCOS Symptoms Semaglutide May Improve
Weight and BMI; insulin resistance and fasting glucose; free testosterone and total androgen levels; menstrual cycle regularity; ovarian volume and follicle count on ultrasound; acne severity; hirsutism (hair growth); and lipid profile. Emotional wellbeing and quality of life also improve significantly in most patients as these symptoms reduce.
Frequently Asked Questions
Q: Does Ozempic help with PCOS?
A: Yes — semaglutide addresses several core mechanisms of PCOS. Insulin resistance is central to PCOS pathophysiology, and semaglutide’s improvements in insulin sensitivity directly reduce androgen production, improve menstrual regularity, and reduce PCOS symptoms. Studies show semaglutide and other GLP-1 medications significantly reduce testosterone levels, improve cycle regularity, and reduce ovarian cyst burden in women with PCOS and overweight/obesity.
Q: Can Ozempic help you get pregnant if you have PCOS?
A: GLP-1 medications can improve fertility in women with PCOS by restoring ovulation through improved insulin sensitivity and reduced androgen levels. Several case series and small trials report resumption of regular menstrual cycles and spontaneous pregnancies in previously anovulatory women after starting semaglutide. However, semaglutide must be stopped before trying to conceive and during pregnancy — consult your reproductive endocrinologist or gynaecologist for a personalised fertility plan.
Q: Is Ozempic approved for PCOS?
A: Semaglutide is not specifically approved for PCOS — it is approved for type 2 diabetes (Ozempic) and weight management (Wegovy). However, its use in PCOS is supported by clinical evidence and increasingly common in endocrinology and gynaecology practice, particularly for women with PCOS and insulin resistance or obesity who are not achieving adequate results with metformin alone.
📖 Further Reading
Start Semaglutide With Specialist Oversight
Physician supervision ensures PCOS-specific monitoring and dosing.
Sponsored | Affiliate link
Affiliate disclosure: Affiliate links present. See our Affiliate Disclosure.